Cite
HARVARD Citation
Reinisch, W. et al. (n.d.). DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn's disease. Journal of Crohn's and colitis. pp. S066-S067. [Online].